Identification of natural potent inhibitors against Mycobacterium tuberculosis isocitrate lyase: an in silico study

• Published in: Molecular diversity
• Main Authors: Rabaan, Ali A, Halwani, Muhammad A, Garout, Mohammed, Turkistani, Safaa A, Alsubki, Roua A, Alawfi, Abdulsalam, Alshengeti, Amer, Najim, Mustafa A, Al Kaabi, Nawal A, Alqazih, Thikrayat Q, Aseeri, Ali A, Bahitham, Afnan S, Alsubaie, Manal A, Alissa, Mohammed, Aljeldah, Mohammed
• Format: Journal Article
• Language: English
• Published: Netherlands 14.08.2023
• Subjects: Isocitrate Lyase; MD simulation; Flavonoids; Drug discovery; Mycobacterium tuberculosis
• ISSN: 1381-1991; 1573-501X
• DOI: 10.1007/s11030-023-10711-w

Tuberculosis (TB) is a global burden to humanity due to its adverse effects on health and society since time is not clearly defined. The existence of drug-resistant strains and the potential threat posed by latent tuberculosis act as strong impetuses for developing novel anti-tuberculosis drugs. In this study, various flavonoids were tested against the Mycobacterium tuberculosis (Mtb) Isocitrate Lyase (ICL), which has been identified as an authorised therapeutic target for treating Mtb infection. Using in silico drug discovery approach, a library of 241 flavonoid compounds was virtually screened against the binding pocket of the crystalline ligand, the VGX inhibitor, in the Mtb ICL protein. As a result, the top four flavonoids were selected based on binding score and were further considered for redocking and intermolecular contact profiling analysis. The global and local fluctuations in the protein and ligand structure were analysed using their root mean square deviation (RMSD) and root mean square fluctuation (RMSF) values obtained from the GROMACS generated 100 ns molecular dynamics (MD) simulation trajectories. The end-state binding free energy was also calculated using the MMPBSA approach for all the respective docked complexes. All four selected compounds exhibited considerable stability and affinity compared to control ligands, i.e. VGX inhibitor; however, Vaccarin showed the highest stability and affinity against the Mtb ICL protein active site, followed by the Genistin, Glabridin, and Corylin. Therefore, this study recommends selected flavonoids for in vitro and in vivo experimental studies to check their potency and efficacy against Mtb.